## AMENDMENTS TO THE CLAIMS

- 1. 13. (Canceled)
- 14. (Withdrawn) A vaccine for preventing or treating gastric cancer, said vaccine containing a recombinant virus or a recombinant bacterium having a DNA encoding a peptide which is a fragment of a gastric cancer antigen protein present in a human gastric cancer cell, said fragment being bound to an HLA molecule and capable of inducing a cytotoxic T cell that targets said gastric cancer cell.
  - 15. (Withdrawn) The vaccine of Claim 14, wherein the HLA molecule is HLA-A31.
- 16. (Withdrawn) The vaccine of Claim 14, wherein said peptide has an amino-acid sequence represented by SEQ ID NO: 1 of the Sequence Listing.
- 17. (Withdrawn) The vaccine of Claim 14, wherein said peptide has an amino-acid sequence represented by SEQ ID NO: 2 of the Sequence Listing.
- 18. (Withdrawn) A method for preventing or treating gastric cancer comprising administering to a patient in need thereof an effective amount of a peptide which is a fragment of a gastric cancer antigen protein present in a human gastric cancer cell, said fragment being bound to an HLA molecule and capable of inducing a cytotoxic T cell that targets said gastric cancer cell.
- 19. (Currently Amended) A method for preventing or treating gastric cancer comprising administering to a patient in need thereof an effective amount of CTL which have been activated with a peptide which is a fragment of a gastric cancer antigen protein present in a human gastric cancer cell, said fragment being bound to an HLA molecule HLA-A3 1 and capable of inducing a cytotoxic T cell that targets said gastric cancer cell;

wherein said peptide which is a fragment of a gastric cancer antigen protein present in a human gastric cancer cell comprises

SEQ. ID. NO. 1 and consists of 10-12 amino acid residues, or

## SEQ. ID. NO. 2 and consists of 9-12 amino acid residues and

wherein said CTL has been activated *in vitro* by adding said peptide to lymphocytes of said patient in need thereof and said administering comprises returning activated CTL to said patient in need thereof.

- 20. (Withdrawn) A method for preventing or treating gastric cancer comprising administering to a patient in need thereof an effective amount of a vaccine containing a recombinant virus or a recombinant bacterium having a DNA encoding a peptide which is a fragment of a gastric cancer antigen protein present in a human gastric cancer cell, said fragment being bound to an HLA molecule and capable of inducing a cytotoxic T cell that targets said gastric cancer cell.
- 21. (New) The method of Claim 19, wherein said peptide which is a fragment of a gastric cancer antigen protein present in a human gastric cancer cell comprises SEQ. ID. NO. 1 and consists of 10-12 amino acid residues.
- 22. (New) The method of Claim 19, wherein said peptide which is a fragment of a gastric cancer antigen protein present in a human gastric cancer cell comprises SEQ. ID. NO. 2 and consists of 9-12 amino acid residues.
- 23. (New) The method of Claim 19, wherein said method is for preventing gastric cancer.
- 24. (New) The method of Claim 19, wherein said method is for treating gastric cancer.
- 25. (New) The method of Claim 19, wherein said lymphocytes are peripheral blood lymphocytes.

## **SUPPORT FOR THE AMENDMENTS**

Claims 1-13 were previously canceled.

Claim 19 has been amended.

Claims 21-25 have been added.

Support for the amendment of Claim 19 and new Claims 21-25 can be found in original Claims 1-20 and the specification at page 17, lines 23 to page 18, line 3. New Claims 21-25 are within the scope of the elected invention and should be examined along with Claim 19.

No new matter has been added by the present amendment.